UBS AM’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-499,048
| Closed | -$12.1M | – | 2739 |
|
|
2023
Q2 | $12.1M | Hold |
499,048
| – | – | 0.01% | 893 |
|
|
2023
Q1 | $12.1M | Buy |
499,048
+379,651
| +318% | +$8.31M | 0.01% | 893 |
|
|
2022
Q4 | $2.56M | Buy |
119,397
+8,590
| +8% | +$183K | ﹤0.01% | 1426 |
|
|
2022
Q3 | $1.99M | Sell |
110,807
-291
| -0.3% | -$3.82K | ﹤0.01% | 1598 |
|
|
2022
Q2 | $1.07M | Buy |
111,098
+16,251
| +17% | +$204K | ﹤0.01% | 1919 |
|
|
2022
Q1 | $1.6M | Buy |
94,847
+17,993
| +23% | +$266K | ﹤0.01% | 1910 |
|
|
2021
Q4 | $1.28M | Buy |
76,854
+10,112
| +15% | +$166K | ﹤0.01% | 2070 |
|
|
2021
Q3 | $1.08M | Sell |
66,742
-14,698
| -18% | -$160K | ﹤0.01% | 2124 |
|
|
2021
Q2 | $514K | Buy |
81,440
+2,589
| +3% | +$16.7K | ﹤0.01% | 2527 |
|
|
2021
Q1 | $487K | Buy |
78,851
+21,451
| +37% | +$130K | ﹤0.01% | 2401 |
|
|
2020
Q4 | $397K | Buy |
+57,400
| New | +$367K | ﹤0.01% | 2361 |
|
|
2016
Q4 | – | Sell |
-17,066
| Closed | -$787K | – | 2707 |
|
|
2016
Q3 | $787K | Buy |
17,066
+2,419
| +17% | +$136K | ﹤0.01% | 1772 |
|
|
2016
Q2 | $748K | Buy |
14,647
+4,108
| +39% | +$204K | ﹤0.01% | 1770 |
|
|
2016
Q1 | $445K | Sell |
10,539
-7,512
| -42% | -$383K | ﹤0.01% | 1986 |
|
|
2015
Q4 | $1.42M | Buy |
18,051
+5,112
| +40% | +$296K | ﹤0.01% | 1607 |
|
|
2015
Q3 | $524K | Buy |
12,939
+2,751
| +27% | +$146K | ﹤0.01% | 1996 |
|
|
2015
Q2 | $530K | Buy |
10,188
+5,188
| +104% | +$258K | ﹤0.01% | 2034 |
|
|
2015
Q1 | $233K | Buy |
+5,000
| New | +$260K | ﹤0.01% | 2407 |
|
UBS AM's ISEE Position: Q3 2023 in Review
UBS AM sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 499,048 shares — an estimated $12.1M sold.
UBS AM first reported a position in ISEE in Q1 2015 and held it in 18 quarters. The position peaked at $12.1M in Q2 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- UBS AM reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- UBS AM sold 499,048 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $12.1M.
- UBS AM first reported a position in IVERIC bio, Inc. Common Stock in Q1 2015 and held it in 18 quarters.
- UBS AM's IVERIC bio, Inc. Common Stock position peaked at $12.1M in Q2 2023.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.